Character Biosciences
PrivateLast Round
Series B
Extension
Sep 17, 2025
Est. Valuation
$197M
Total Funding Raised
$134M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Character Biosciences operates in Healthcare & Life Sciences and is based in Jersey City, New Jersey. Its latest recorded funding round was a Series B Extension round in September 2025.
Character Biosciences is a biotechnology company that develops precision medicine and targeted therapies for progressive polygenic diseases, with an initial focus on ophthalmology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Healthcare Analytics, Medical Imaging
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Character Biosciences Comparables
Compare Character Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genomics | 77% | |
| Quotient Therapeutics | 75% | |
| Recursion Pharmaceuticals | 73% |
For institutional investors. Book with your work email.
Character Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 17, 2025 | ||||
| Series B | Mar 25, 2025 | ||||
| Series A | May 17, 2022 | ||||
| Seed | Mar 1, 2020 |
For institutional investors. Book with your work email.
Character Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A, Series B |
| Cantos Ventures | Series A, Seed |
| Innovation Endeavors | Series B Extension, Series B, Series A |
| Lifeforce Capital | Series A, Seed |
| Catalio Capital Management | Series B Extension, Series A, Series B |
| LUMA Partners | Series B |
| Jefferson Life Sciences | Series B Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 143% MoM.
- Jun 24, 2026
Grew 16% QoQ, from 49 to 57 employees.
For institutional investors. Book with your work email.
Character Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Character Biosciences's valuation, stock price, and market status.
Is Character Biosciences a public or private company?
Character Biosciences is a private company.
What is the current stock price of Character Biosciences?
Character Biosciences is a private company, so its shares have no public market price. Caplight tracks Character Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Character Biosciences worth (valuation)?
Character Biosciences's valuation is estimated at $197.0M based on funding round data.
Can I buy Character Biosciences stock?
Character Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Character Biosciences's last funding round?
Character Biosciences's most recent funding round was Series B Extension on September 17, 2025.
Who are the main investors in Character Biosciences?
Key investors in Character Biosciences include Innovation Endeavors, LUMA Partners, aMoon, Luma Group.
Will Character Biosciences IPO soon?
No public IPO plans have been announced for Character Biosciences.
How can I track Character Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Character Biosciences's shares on secondary markets.